These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15180645)

  • 1. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy.
    Stephan C; Lein M; Schnorr D; Loening SA; Jung K
    BJU Int; 2004 Jun; 93(9):1360-1. PubMed ID: 15180645
    [No Abstract]   [Full Text] [Related]  

  • 2. [Significance of re-measurement of prostate specific antigen before prostate biopsy].
    Saito T; Kitamura Y; Komatsubara S
    Hinyokika Kiyo; 2006 Oct; 52(10):773-6. PubMed ID: 17131865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial comment on: reassessing the diagnostic yield of saturation biopsy of the prostate.
    Philip J
    Eur Urol; 2008 May; 53(5):981-2. PubMed ID: 17997013
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial comment on: reassessing the diagnostic yield of saturation biopsy of the prostate.
    Patel A
    Eur Urol; 2008 May; 53(5):982-3. PubMed ID: 17997023
    [No Abstract]   [Full Text] [Related]  

  • 5. Saturation technique does not decrease cancer detection during followup after initial prostate biopsy.
    Lane BR; Zippe CD; Abouassaly R; Schoenfield L; Magi-Galluzzi C; Jones JS
    J Urol; 2008 May; 179(5):1746-50; discussion 1750. PubMed ID: 18343412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy.
    Mishra VC; Motiwala HG
    BJU Int; 2004 May; 93(7):1116-7. PubMed ID: 15142181
    [No Abstract]   [Full Text] [Related]  

  • 7. [Prostatic punch biopsy].
    Braun M; Engelmann U
    Aktuelle Urol; 2006 Jul; 37(4):291-302. PubMed ID: 16897646
    [No Abstract]   [Full Text] [Related]  

  • 8. Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
    Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
    Prostate Cancer Prostatic Dis; 2009; 12(1):47-51. PubMed ID: 18762815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Two major diagnostic innovations in the management of prostate cancer].
    Doublet JD; Cornu JN; Rouprêt M
    Prog Urol; 2007 Apr; 17(2 Suppl 1):285-6. PubMed ID: 17569271
    [No Abstract]   [Full Text] [Related]  

  • 10. Verification bias in screening for prostate cancer.
    Chatterton HT
    N Engl J Med; 2003 Oct; 349(17):1672-3; author reply 1672-3. PubMed ID: 14575055
    [No Abstract]   [Full Text] [Related]  

  • 11. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
    Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
    Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidental acute prostatic inflammation is associated with a lower percentage of free prostate-specific antigen than other benign conditions of the prostate: a prospective screening study.
    Rowe EW; Laniado ME; Walker MM; Anup P
    BJU Int; 2006 May; 97(5):1039-42. PubMed ID: 16643488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verification bias and the prostate-specific antigen test--is there a case for a lower threshold for biopsy?
    Schröder FH; Kranse R
    N Engl J Med; 2003 Jul; 349(4):393-5. PubMed ID: 12878747
    [No Abstract]   [Full Text] [Related]  

  • 14. The prostate biopsy.
    Harv Mens Health Watch; 2003 Jul; 7(12):4-7. PubMed ID: 12888462
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate cancer with low PSA levels.
    Glaser AI
    N Engl J Med; 2004 Oct; 351(17):1802-3. PubMed ID: 15499670
    [No Abstract]   [Full Text] [Related]  

  • 16. Verification bias in screening for prostate cancer.
    Leiner S
    N Engl J Med; 2003 Oct; 349(17):1672-3; author reply 1672-3. PubMed ID: 14573742
    [No Abstract]   [Full Text] [Related]  

  • 17. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
    Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
    BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
    Shao Q; Song J; Zhou ZJ; Du LD
    Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer detection in men with a 'normal' total prostate-specific antigen (PSA) level using percentage free PSA: a prospective screening study.
    Rowe EW; Laniado ME; Walker MM; Patel A
    BJU Int; 2005 Jun; 95(9):1249-52. PubMed ID: 15892810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The performance of prostate specific antigen, prostate specific antigen density and transition zone density in the era of extended biopsy schemes.
    Elliott CS; Shinghal R; Presti JC
    J Urol; 2008 May; 179(5):1756-61; discussion 1761. PubMed ID: 18343425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.